アルビナス
Arvinas, Inc.
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | 2.61 | $250M | -$49M |
| 2026 Q1 | -0.90 | $16M | -$71M |
| 2025 Q4 | -1.04 | $10M | -$31M |
| 2025 Q3 | -0.48 | $42M | -$59M |
| 2025 Q2 | -0.84 | $22M | -$97M |
| 2025 Q1 | 1.14 | $189M | -$89M |
| 2024 Q4 |
| -0.63 |
| $59M |
| -$84M |
| 2024 Q3 | -0.68 | $102M | -$129M |